Previous 10 | Next 10 |
2023-05-08 07:32:14 ET Akebia press release ( NASDAQ: AKBA ): Q1 GAAP EPS of -$0.14 beats by $0.01 . Revenue of $40.13M (-35.0% Y/Y) misses by $6.55M . For further details see: Akebia GAAP EPS of -$0.14 beats by $0.01, revenue of $40.13M misses by $6.55M
Akebia Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights PR Newswire Akebia to host conference call on May 8 at 8:30 a.m. ET Announced vadadustat is now approved in 32 countries following European Commission marketing auth...
2023-05-05 12:16:50 ET Akebia ( NASDAQ: AKBA ) is scheduled to announce Q1 earnings results on Monday, May 8th, before market open. The consensus EPS Estimate is -$0.15 (+57.1% Y/Y) and the consensus Revenue Estimate is $46.68M (-24.3% Y/Y). Over the last 3 months, EPS...
2023-05-05 11:40:34 ET Major earning expected before the bell on Monday include: BioNTech ( BNTX ) DISH Network ( DISH ) KKR & Co. ( KKR ) Tyson Foods ( TSN ) Viatris ( VTRS ) For further details see: Notable earnings before Monday's open
Akebia Therapeutics to Report First Quarter Financial Results and Discuss Recent Business Highlights PR Newswire Akebia to Host Conference Call CAMBRIDGE, Mass. , May 1, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical co...
2023-04-27 11:12:14 ET Numerous factors must be considered as you search for penny stocks to buy in the current market. Emotions are running high, from overarching recession and inflation narratives to the potential for a stock market crash in 2023. This has led to increased volatility ...
Akebia Receives European Commission Approval for Vafseo™ (vadadustat) for the Treatment of Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis PR Newswire CAMBRIDGE, Mass. , April 25, 2023 /PRNewswire/ -- ...
2023-04-14 09:09:57 ET Kidney-disease drug developer Akebia Therapeutics ( NASDAQ: AKBA ) lost ~5% pre-market Friday after announcing a decision to implement a reverse stock split. The move is aimed at regaining compliance with the Nasdaq listing rule related to the minimu...
Akebia Therapeutics to Host Stockholder Information Session to Discuss Rationale for Reverse Stock Split PR Newswire Webcast Scheduled for Friday, April 21 at 8:00 a.m. ET Stockholders are invited to submit questions in advance CAMBRIDGE, Mass. , ...
Akebia Therapeutics Announces Adjournment of Special Meeting of Stockholders PR Newswire Meeting adjourned to Thursday, May 4, 2023 at 10:00 a.m. Eastern Time CAMBRIDGE, Mass. , April 11, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKB...
News, Short Squeeze, Breakout and More Instantly...
Akebia Therapeutics Inc. Company Name:
AKBA Stock Symbol:
NASDAQ Market:
Akebia Therapeutics Inc. Website:
Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets PR Newswire Akebia regains full rights to sell Vafseo® (vadadustat) Tablets in the U.S. following the execution of a royalty-based termination agreement wit...
Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference PR Newswire CAMBRIDGE, Mass. , June 27, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purp...
Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer PR Newswire CAMBRIDGE, Mass. , June 24, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with t...